Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical impact of mucus plugs in bronchiectasis.

Scientific reports·2026
Same author

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same author

A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.

Journal of clinical medicine·2026
Same author

Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials.

American journal of respiratory and critical care medicine·2026
Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026
Same author

Radiomic analysis of computed tomography scans in COPD patients relates to different clinical and biological features, and identifies different lung function trajectories during follow-up.

ERJ open research·2026
Same journal

Thoracic Sympathectomy for Harlequin Syndrome.

Archivos de bronconeumologia·2026
Same journal

Prognostic Significance of Electrocardiographic Findings in Hemodynamically Stable Patients With Acute Pulmonary Embolism: Insights From the RIETE Registry.

Archivos de bronconeumologia·2026
Same journal

Endothelial and Angiogenic Biomarkers in Obstructive Sleep Apnea: Longitudinal Associations With Continuous Positive Airway Pressure.

Archivos de bronconeumologia·2026
Same journal

Robotic Resection of Ectopic Paratracheal Thymoma: A Case Report.

Archivos de bronconeumologia·2026
Same journal

Real-World Effectiveness of Tezepelumab Across T2 and Non-T2 Severe Asthma Phenotypes: A Multicenter Spanish Cohort Study.

Archivos de bronconeumologia·2026
Same journal

Mitochondrial Dysfunction and Telomeric Shortening as Long-term Complications After COVID-19.

Archivos de bronconeumologia·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells
09:15

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

Published on: May 11, 2020

[COPD and systemic inflammation. A link for comorbidity].

Alvar Agustí1

  • 1Institut del Tòrax, Hospital Clínic, Universitat de Barcelona, CIBER Enfermedades Respiratorias, Fundación Caubet-Cimera, Illes Balears, España. alvar.agusti@clinic.ub.es

Archivos De Bronconeumologia
|February 2, 2010
PubMed
Summary
This summary is machine-generated.

Systemic inflammation in chronic obstructive pulmonary disease (COPD) is linked to other health conditions. However, its definition, origins, and impact remain unproven, requiring further research.

Related Experiment Videos

Last Updated: Jun 16, 2026

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells
09:15

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

Published on: May 11, 2020

Area of Science:

  • Pulmonary Medicine
  • Inflammation Research
  • Comorbidity Studies

Context:

  • Chronic obstructive pulmonary disease (COPD) patients often present with multiple comorbidities.
  • Systemic inflammation is hypothesized as a key factor linking COPD and comorbidity.
  • Existing research on this association is limited and requires further investigation.

Purpose:

  • To critically review the current understanding of systemic inflammation in COPD patients with comorbidities.
  • To highlight the challenges in defining and measuring systemic inflammation in this population.
  • To evaluate the evidence supporting the link between systemic inflammation and comorbidity in COPD.

Summary:

  • There is no universally accepted definition for systemic inflammation in COPD.
  • The prevalence of systemic inflammation varies significantly based on the markers used.
  • The origin of systemic inflammation is likely multifactorial, and its association with comorbidity in COPD is currently circumstantial.
  • Evidence regarding the effect of inhaled glucocorticosteroids on systemic inflammation is contradictory.

Impact:

  • Highlights the unproven nature of the association between systemic inflammation and comorbidity in COPD.
  • Identifies critical knowledge gaps in understanding systemic inflammation in COPD.
  • Underscores the need for standardized definitions and further research to clarify the role of systemic inflammation.